C4 Therapeutics (CCCC) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $2.77, -0.54% vs the prior close of $2.78.
- Volume 2.36M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
CCCC dips 0.5% to $2.77. Closed at $2.77, -0.54% vs the prior close of $2.78. Day range $2.69–$2.81, opened at $2.78.
CCCC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — CCCC dips 0.5% to $2.77
- Closed at $2.77, -0.54% vs the prior close of $2.78. Day range $2.69–$2.81, opened at $2.78.
- Volume was 2.36M shares, 1.0x its 50-day average of 2.28M.
- Price is -20.8% vs its 50-day average ($3.49) and -12.4% vs its 200-day average ($3.15).
- 52-week range $1.69–$5.17; today's close sits at 31% of that range, 46.5% below the 52-week high.
Oct 15, 2026 — CCCC jumps 6.5% to $2.78
- Closed at $2.78, +6.51% vs the prior close of $2.61. Day range $2.60–$2.85, opened at $2.64.
- Volume was 3.27M shares, 1.4x its 50-day average of 2.26M.
- Price is -20.8% vs its 50-day average ($3.51) and -11.8% vs its 200-day average ($3.15).
- 52-week range $1.69–$5.17; today's close sits at 31% of that range, 46.2% below the 52-week high.
Oct 14, 2026 — CCCC slides 6.1% to $2.61, a 3-month low, 3 down days in a row
- Closed at $2.61, -6.12% vs the prior close of $2.78. Day range $2.59–$2.80, opened at $2.72.
- Volume was 3.09M shares, 1.4x its 50-day average of 2.25M.
- Price is -26.0% vs its 50-day average ($3.53) and -17.1% vs its 200-day average ($3.15).
- 52-week range $1.69–$5.17; today's close sits at 26% of that range, 49.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — CCCC slides 9.2% to $2.78, a 3-month low
- Closed at $2.78, -9.15% vs the prior close of $3.06. Day range $2.75–$3.06, opened at $3.04.
- Volume was 3.82M shares, 1.7x its 50-day average of 2.22M.
- Price is -21.6% vs its 50-day average ($3.55) and -11.6% vs its 200-day average ($3.14).
- 52-week range $1.69–$5.17; today's close sits at 31% of that range, 46.2% below the 52-week high.
Oct 12, 2026 — CCCC slides 3.2% to $3.06
- Closed at $3.06, -3.16% vs the prior close of $3.16. Day range $3.05–$3.30, opened at $3.16.
- Volume was 1.50M shares, 0.7x its 50-day average of 2.23M.
- Price is -14.0% vs its 50-day average ($3.56) and -2.6% vs its 200-day average ($3.14).
- 52-week range $1.69–$5.17; today's close sits at 39% of that range, 40.8% below the 52-week high.
Oct 9, 2026 — CCCC jumps 10.9% to $3.16
- Closed at $3.16, +10.88% vs the prior close of $2.85. Day range $2.95–$3.19, opened at $3.00.
- Volume was 2.51M shares, 1.1x its 50-day average of 2.24M.
- Price is -11.4% vs its 50-day average ($3.57) and +0.8% vs its 200-day average ($3.14).
- 52-week range $1.69–$5.17; today's close sits at 42% of that range, 38.9% below the 52-week high.
Oct 8, 2026 — CCCC rises 1.1% to $2.85
- Closed at $2.85, +1.06% vs the prior close of $2.82. Day range $2.72–$2.88, opened at $2.80.
- Volume was 2.83M shares, 1.3x its 50-day average of 2.23M.
- Price is -20.4% vs its 50-day average ($3.58) and -9.0% vs its 200-day average ($3.13).
- 52-week range $1.69–$5.17; today's close sits at 33% of that range, 44.9% below the 52-week high.
Oct 7, 2026 — CCCC dips 2.1% to $2.82, a 3-month low
- Closed at $2.82, -2.08% vs the prior close of $2.88. Day range $2.82–$2.95, opened at $2.85.
- Volume was 2.27M shares, 1.0x its 50-day average of 2.23M.
- Price is -21.5% vs its 50-day average ($3.59) and -9.8% vs its 200-day average ($3.13).
- 52-week range $1.69–$5.17; today's close sits at 32% of that range, 45.5% below the 52-week high.
Oct 6, 2026 — CCCC slides 3.7% to $2.88, a 3-month low
- Closed at $2.88, -3.68% vs the prior close of $2.99. Day range $2.79–$3.03, opened at $3.02.
- Volume was 2.11M shares, 0.9x its 50-day average of 2.27M.
- Price is -20.1% vs its 50-day average ($3.61) and -7.8% vs its 200-day average ($3.12).
- 52-week range $1.69–$5.17; today's close sits at 34% of that range, 44.3% below the 52-week high.
Oct 5, 2026 — CCCC rises 1.4% to $2.99
- Closed at $2.99, +1.36% vs the prior close of $2.95. Day range $2.95–$3.10, opened at $3.01.
- Volume was 1.46M shares, 0.6x its 50-day average of 2.30M.
- Price is -17.4% vs its 50-day average ($3.62) and -4.1% vs its 200-day average ($3.12).
- 52-week range $1.69–$5.17; today's close sits at 37% of that range, 42.2% below the 52-week high.
Oct 2, 2026 — CCCC slides 6.1% to $2.95, a 3-month low
- Closed at $2.95, -6.05% vs the prior close of $3.14. Day range $2.93–$3.33, opened at $3.19.
- Volume was 3.38M shares, 1.5x its 50-day average of 2.27M.
- Price is -18.7% vs its 50-day average ($3.63) and -5.3% vs its 200-day average ($3.11).
- 52-week range $1.69–$5.17; today's close sits at 36% of that range, 42.9% below the 52-week high.
CCCC latest news & SEC filings
Every SEC filing by or about CCCC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Anderson Kenneth Carl received an award of 3,662 shares at $3.14 (≈$11.50K) on Oct 1, 2026; now holds 75,612
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Grogan Donna Roy received an award of 4,618 shares at $3.14 (≈$14.50K) on Oct 1, 2026; now holds 79,471
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Adams Kendra converted options/RSUs into 6,250 shares on Sep 18, 2026; now holds 385,098
- Adams Kendra had withheld for taxes 2,775 shares at $3.39 (≈$9.41K) on Sep 18, 2026; now holds 382,323
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $6.64M (prior year $6.46M) (+2.8% vs Jun 30, 2025)
- Net income: -$23.64M (prior year -$26.02M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.18 (prior year -$0.37) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade CCCC
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.04% (largest 10.9%). That is a volatile stock.
- Liquidity: about 2.52M shares (≈$6.96M) trade per day on average.
- 52-week position: $2.77 vs a range of $1.69–$5.17 (31% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Leonard Reyno sold 10,000 shares on Jan 16, 2026.
- Latest filings: 8-K Sep 25, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 123.03M shares outstanding (Jul 31, 2026), +72.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
CCCC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 2.78 | 2.81 | 2.69 | 2.77 | 2.36M |
| Oct 15, 2026 | 2.64 | 2.85 | 2.60 | 2.78 | 3.27M |
| Oct 14, 2026 | 2.72 | 2.80 | 2.59 | 2.61 | 3.09M |
| Oct 13, 2026 | 3.04 | 3.06 | 2.75 | 2.78 | 3.82M |
| Oct 12, 2026 | 3.16 | 3.30 | 3.05 | 3.06 | 1.50M |
| Oct 9, 2026 | 3.00 | 3.19 | 2.95 | 3.16 | 2.51M |
| Oct 8, 2026 | 2.80 | 2.88 | 2.72 | 2.85 | 2.83M |
| Oct 7, 2026 | 2.85 | 2.95 | 2.82 | 2.82 | 2.27M |
| Oct 6, 2026 | 3.02 | 3.03 | 2.79 | 2.88 | 2.11M |
| Oct 5, 2026 | 3.01 | 3.10 | 2.95 | 2.99 | 1.46M |
| Oct 2, 2026 | 3.19 | 3.33 | 2.93 | 2.95 | 3.38M |
| Oct 1, 2026 | 3.31 | 3.37 | 3.13 | 3.14 | 1.89M |
| Sep 30, 2026 | 3.16 | 3.37 | 3.13 | 3.33 | 2.61M |
| Sep 29, 2026 | 3.09 | 3.21 | 3.00 | 3.13 | 1.55M |
| Sep 28, 2026 | 3.02 | 3.16 | 2.98 | 3.12 | 2.78M |
| Sep 25, 2026 | 3.03 | 3.12 | 2.92 | 2.98 | 2.12M |
| Sep 24, 2026 | 3.03 | 3.06 | 2.88 | 3.03 | 2.81M |
| Sep 23, 2026 | 3.32 | 3.34 | 2.92 | 3.08 | 4.59M |
| Sep 22, 2026 | 3.33 | 3.42 | 3.29 | 3.31 | 1.36M |
| Sep 21, 2026 | 3.44 | 3.45 | 3.24 | 3.30 | 2.05M |
About C4 Therapeutics
C4 Therapeutics (CCCC) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in WATERTOWN, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1662579.
CCCC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kenneth Carl Anderson | Director | Jul 2, 2026 |
| Laura Bessen | Director | Jun 26, 2026 |
| Ronald Harold Wilfred Cooper | Director | Jun 26, 2026 |
| Stephen Fawell | Director | Jun 26, 2026 |
| Donna Roy Grogan | Director | Jul 2, 2026 |
| Andrew Hirsch | President & CEO | Feb 18, 2026 |
| Steven L. Hoerter | Director | Jun 26, 2026 |
| Owen Hughes | Director | Jun 26, 2026 |
| Utpal Koppikar | Director | Jun 26, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kendra Adams | Chief Financial Officer | Sep 21, 2026 |
| Scott N Boyle | Chief Business Officer | Feb 18, 2026 |
| Andrew Hirsch | President & CEO | Feb 18, 2026 |
| Paige Mahaney | Chief Scientific Officer | Feb 18, 2026 |
| Mark Mossler | Chief Accounting Officer | Feb 18, 2026 |
| Leonard Reyno | Chief Medical Officer | Jul 13, 2026 |
| Kelly Schick | Chief People Officer | Feb 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jan 16, 2026 | Leonard Reyno | Sale | 10,000 | $2.22 |
| Jan 16, 2026 | Leonard Reyno | Sale | 10,000 | $2.22 |
| Jan 16, 2026 | Leonard Reyno | Sale | 10,000 | $2.22 |
| Jan 16, 2026 | Leonard Reyno | Sale | 10,000 | $2.22 |
CCCC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $35.95M | $-104.99M | -1.27 | $-98.69M |
| Dec 31, 2024 | $35.58M | $-105.32M | -1.52 | $-65.16M |
| Dec 31, 2023 | $20.76M | $-132.49M | -2.67 | $-106.84M |
| Dec 31, 2022 | $31.10M | $-128.18M | -2.62 | $-105.94M |
| Dec 31, 2021 | $45.78M | $-83.89M | -1.82 | $-86.97M |
Latest balance sheet: total assets $359.40M, total liabilities $112.14M, cash $78.61M (as of Jun 30, 2026).
CCCC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $3.87 |
| May 12, 2026 | 8-K Item 2.02 (results) | $3.17 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $2.78 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $2.38 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $2.58 |
| May 7, 2025 | 8-K Item 2.02 (results) | $1.50 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $2.60 |
| Jan 14, 2025 | 8-K Item 2.02 (results) | $3.74 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $5.33 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 22, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on CCCC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.